Sector |
|
Compare with Sector peers |
Industry |
|
Compare with Industry peers |
Website | http://www.glenmarkpharma.com | |
Market Cap | 12,398.47 Cr. | |
Enterprise Value(EV) | 15,270.50 Cr. | 2022-09 |
Financial Indicators | ||
---|---|---|
Earnings per share (EPS) | 31.23 | Trailing Twelve Months Ending 2022-12 |
Price-Earning Ratio (PE) | 14.07 | Trailing Twelve Months Ending 2022-12 |
Industry PE | 31.71 | Trailing Twelve Months Ending 2022-12 |
Book Value / Share | 349.11 | Trailing Twelve Months Ending 2022-12 |
Price to Book Value | 1.26 | Calculated using Price: 439.40 |
Dividend Yield | 0.57 | Period Ending 2022-03 |
No. of Shares Subscribed | 28.22 Cr. | 282,168,156 Shares |
FaceValue | 1 | |
Company Profile | ||
The Company is engaged in the development of new chemical entities (NCEs) and new biological entities (NBEs). Specialty Business: Drug Discovery: Glenmark's ground-breaking drug discovery effort is primarily focused in the areas of inflammation [asthma/COPD, rheumatoid arthritis etc.], metabolic disorders [diabetes, obesity, etc.] and pain [neuropathic pain and inflammatory pain]. Specialty Business: Formulations Business: Glenmark's formulations business is currently organized many regions - India, Latin America, Central Eastern Europe and Semi Regulated Markets of Africa/Asia/CIS. The formulations business focuses on therapeutic areas viz. dermatology, anti-infective, respiratory, cardiac, diabetes, gynecology, CNS, and oncology. |
1 Day |
|
-2.22% |
1 Week |
|
+4.54% |
1 Month |
|
-0.08% |
3 Month |
|
-1.33% |
6 Month |
|
+13.74% |
1 Year |
|
-4.63% |
2 Year |
|
-5.14% |
5 Year |
|
-20.17% |
10 Year |
|
-11.99% |
9 years | 2014-03 | 2015-03 | 2016-03 | 2017-03 | 2018-03 | 2019-03 | 2020-03 | 2021-03 | 2022-03 | |
Return on Equity (%) | 18.99 | 8.79 | 27.46 | 27.31 | 16.67 | 17.21 | 13.32 | 14.81 | 12.33 | |
Return on Capital Employed (%) | 15.04 | 12.40 | 18.53 | 20.54 | 14.77 | 16.47 | 14.04 | 15.30 | 14.19 | |
Return on Assets (%) | 7.51 | 2.58 | 8.52 | 11.33 | 7.40 | 7.98 | 6.17 | 7.11 | 6.74 |
Particulars | 10 years | 2014-03 Rs. Cr. | 2015-03 Rs. Cr. | 2016-03 Rs. Cr. | 2017-03 Rs. Cr. | 2018-03 Rs. Cr. | 2019-03 Rs. Cr. | 2020-03 Rs. Cr. | 2021-03 Rs. Cr. | 2022-03 Rs. Cr. | 2022-09* Rs. Cr. |
Shh. Funds | 2,983 | 1,783 | 3,630 | 4,493 | 5,163 | 5,605 | 6,071 | 7,065 | 9,087 | 9,573 | |
Non Curr. Liab. | 1,967 | 2,749 | 1,499 | 3,258 | 2,824 | 2,280 | 3,033 | 2,804 | 1,270 | 2,342 | |
Curr. Liab. | 2,949 | 3,777 | 3,999 | 2,703 | 3,288 | 4,021 | 4,126 | 4,201 | 4,689 | 4,198 | |
Minority Int. | 13 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 351 | 366 | |
Equity & Liab. | 7,912 | 8,309 | 9,128 | 10,453 | 11,275 | 11,906 | 13,229 | 14,069 | 15,397 | 16,479 | |
Non Curr. Assets | 3,150 | 2,978 | 3,224 | 3,578 | 4,286 | 5,209 | 6,425 | 6,709 | 7,115 | 7,520 | |
Curr. Assets | 4,763 | 5,331 | 5,904 | 6,875 | 6,989 | 6,697 | 6,804 | 7,360 | 8,282 | 8,959 | |
Misc. Exp. not W/O | |||||||||||
Total Assets | 7,912 | 8,309 | 9,128 | 10,453 | 11,275 | 11,906 | 13,229 | 14,069 | 15,397 | 16,479 |
Particulars | 10 years | 2014-03 Rs. Cr. | 2015-03 Rs. Cr. | 2016-03 Rs. Cr. | 2017-03 Rs. Cr. | 2018-03 Rs. Cr. | 2019-03 Rs. Cr. | 2020-03 Rs. Cr. | 2021-03 Rs. Cr. | 2022-03 Rs. Cr. | 2022-12 Rs. Cr. TTM |
Net Sales | 5,945 | 6,681 | 7,562 | 9,079 | 9,074 | 9,865 | 10,641 | 10,944 | 12,305 | 12,636 | |
Other Income | 11 | 7 | 20 | 37 | 91 | 208 | 160 | 50 | 167 | 464 | |
Total Income | 5,956 | 6,688 | 7,582 | 9,117 | 9,166 | 10,074 | 10,801 | 10,994 | 12,472 | 13,100 | |
Total Expenditure | -4,854 | -5,467 | -6,125 | -7,043 | -7,459 | -8,280 | -8,943 | -8,860 | -9,985 | -10,499 | |
PBIDT | 1,102 | 1,221 | 1,457 | 2,074 | 1,707 | 1,794 | 1,858 | 2,135 | 2,487 | 2,601 | |
Interest | -189 | -190 | -179 | -237 | -286 | -335 | -377 | -353 | -298 | -327 | |
Depreciation | -217 | -300 | -234 | -264 | -302 | -326 | -417 | -444 | -487 | -596 | |
Taxation | -151 | -334 | -301 | -383 | -315 | -376 | -320 | -412 | -448 | -676 | |
Exceptional Items | -187 | -81 | 167 | 33 | 45 | -261 | -49 | ||||
PAT | 546 | 209 | 743 | 1,109 | 804 | 925 | 776 | 970 | 994 | 953 | |
Minority Interest | -3 | 0 | 0 | 0 | 0 | 0 | 0 | -52 | -72 | ||
Share Associate | |||||||||||
Other Related Items | |||||||||||
Consolidated Net Profit | 542 | 210 | 743 | 1,109 | 804 | 925 | 776 | 970 | 942 | 881 | |
Adjusted EPS | 20 | 8 | 26 | 39 | 28 | 33 | 28 | 34 | 33 | 31 |
Particulars | 10 years | 2013-03 Rs. Cr. | 2014-03 Rs. Cr. | 2015-03 Rs. Cr. | 2016-03 Rs. Cr. | 2017-03 Rs. Cr. | 2018-03 Rs. Cr. | 2019-03 Rs. Cr. | 2020-03 Rs. Cr. | 2021-03 Rs. Cr. | 2022-03 Rs. Cr. |
Cash Fr. Operatn. | 648 | 854 | 482 | 345 | 657 | 1,648 | 1,324 | 1,392 | 1,131 | 1,109 | |
Cash Fr. Inv. | -464 | -368 | -540 | -880 | -712 | -1,013 | -699 | -784 | -675 | -333 | |
Cash Fr. Finan. | 195 | -98 | 199 | 699 | 543 | -469 | -739 | -445 | -442 | -520 | |
Net Change | 379 | 388 | 141 | 163 | 488 | 166 | -114 | 164 | 14 | 255 | |
Cash & Cash Eqvt | 605 | 795 | 764 | 857 | 1,056 | 1,233 | 936 | 1,110 | 1,138 | 1,411 |
Mon, 20 Mar 2023
Announcement under Regulation 30 (LODR)-Press Release / Media Release Glenmark Pharmaceuticals receives ANDA approval for Prochlorperazine Maleate Tablets USP 5 mg and 10 mg |
Thu, 16 Mar 2023
Announcement under Regulation 30 (LODR)-Newspaper Publication Pursuant to Regulation 47 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations 2015 we hereby enclose copies of the newspaper advertisement informing about Postal Ballot Notice and e-Voting information published in Financial Express and Loksatta dated 15th March 2023. The same has been made available on the Companys website. |
Thu, 16 Mar 2023
Announcement under Regulation 30 (LODR)-Press Release / Media Release Glenmark receives acceptance from U.S. FDA on its IND application for GRC 54276 to proceed with a Phase 1/2 first-in-human clinical study of the molecule for the treatmentof patients with advanced solid tumors and lymphomas |
Mon, 20 Mar 2023 |
|
|
|
|
|